Checkpoint Therapeutics Announces Merger Progress

Published 22/05/2025, 13:24
Checkpoint Therapeutics Announces Merger Progress

Checkpoint Therapeutics , Inc. (NASDAQ:CKPT), trading near its 52-week high of $4.50 with a market capitalization of $350 million, announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) expired on May 21, 2025, marking a significant step towards completing its merger with Sun Pharmaceutical (TADAWUL:2070) Industries, Inc. According to InvestingPro, the stock has delivered an impressive 125% return over the past year. This expiration satisfies one of the conditions for the finalization of the merger, which is expected to occur around May 30, 2025.

The merger, initially disclosed on March 9, 2025, and subsequently amended on April 14, 2025, involves Sun Pharma’s subsidiary, Snoopy Merger Sub, Inc., merging with Checkpoint, which will continue as a wholly owned subsidiary of Sun Pharma post-merger. InvestingPro analysis indicates the company currently holds more cash than debt on its balance sheet, potentially strengthening its position in the merger negotiations. For deeper insights into merger implications and more exclusive tips, consider exploring InvestingPro’s comprehensive analysis tools. Checkpoint filed a preliminary proxy statement on April 14, 2025, followed by a definitive proxy statement on April 23, 2025, and began mailing the definitive proxy statement to its stockholders on the same day.

Checkpoint also reported that a consolidated putative stockholder class action lawsuit pending in the Southern District of New York against the company and its President and CEO, James Oliviero, was dismissed with prejudice on May 19, 2025. The lawsuit alleged violations of the Securities Exchange Act of 1934 and SEC Rule 10b-5 due to purported false and misleading statements. The plaintiff has a 30-day window from May 19, 2025, to appeal the judgment.

The company’s stockholders will vote on the adoption of the Merger Agreement at a Special Meeting scheduled to take place virtually on May 28, 2025, at 10:00 a.m. Eastern time. While the company’s financial health score is currently rated as weak by InvestingPro, analysts anticipate significant sales growth in the current year, which could influence stockholder decisions.

Checkpoint’s management cautions that forward-looking statements in this report are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated. The company intends to defend vigorously if the judgment in the Securities Class Action (WA:ACT) is appealed.

The merger is subject to the approval of Checkpoint’s stockholders and other customary closing conditions. Additional information regarding the merger and where to find it, along with details of the participants in the solicitation, can be found in the definitive proxy statement and Checkpoint’s filings with the SEC.

The information in this news article is based on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.